Deutsche Bank AG Invests $5.09 Million in Adaptive Biotechnologies Corporation $ADPT

Key Points

• Deutsche Bank acquired 237,406 shares of Adaptive Biotechnologies worth approximately $5.09 million, while institutional investors collectively own 99.17% of the company.
• Adaptive Biotechnologies reported quarterly revenue of $71.55 million, up 21.5% year over year and above estimates, but its loss of $0.25 per share exceeded the expected $0.13 loss.
• Shares opened at $25.55 near their 52-week high, with analysts maintaining a “Moderate Buy” consensus and an average price target of $24.42; meanwhile, insiders sold more than 2 million shares worth $46.7 million over three months.

Deutsche Bank AG acquired a new stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 237,406 shares of the company's stock, valued at approximately $5,092,000. Deutsche Bank AG owned about 0.15% of Adaptive Biotechnologies as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. 1492 Capital Management LLC bought a new stake in Adaptive Biotechnologies during the 4th quarter worth about $1,484,000. Jupiter Asset Management Ltd. grew its holdings in shares of Adaptive Biotechnologies by 33.8% in the 4th quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company's stock valued at $5,892,000 after acquiring an additional 91,683 shares in the last quarter. Rhenman & Partners Asset Management AB grew its holdings in shares of Adaptive Biotechnologies by 22.2% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 605,000 shares of the company's stock valued at $9,825,000 after acquiring an additional 110,000 shares in the last quarter. Westfield Capital Management Co. LP acquired a new stake in shares of Adaptive Biotechnologies in the fourth quarter valued at about $65,942,000. Finally, Jennison Associates LLC raised its holdings in Adaptive Biotechnologies by 103.9% during the fourth quarter. Jennison Associates LLC now owns 2,674,668 shares of the company's stock worth $43,437,000 after acquiring an additional 1,363,181 shares in the last quarter. Institutional investors and hedge funds own 99.17% of the company's stock.

Adaptive Biotechnologies Price Performance

Shares of ADPT opened at $25.55 on Tuesday. The company's 50-day moving average is $22.22 and its 200-day moving average is $17.39. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68. The firm has a market capitalization of $4.08 billion, a PE ratio of -62.32 and a beta of 2.08. Adaptive Biotechnologies Corporation has a fifty-two week low of $12.00 and a fifty-two week high of $26.16.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last announced its earnings results on Wednesday, July 29th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The company had revenue of $71.55 million for the quarter, compared to the consensus estimate of $65.44 million. During the same period in the previous year, the firm posted ($0.17) EPS. The business's quarterly revenue was up 21.5% on a year-over-year basis. Equities analysts forecast that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ADPT shares. TD Cowen increased their price target on Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a "buy" rating in a research report on Thursday, July 30th. Piper Sandler boosted their price target on Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an "overweight" rating in a research report on Tuesday, August 4th. Guggenheim upped their price objective on Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a "buy" rating in a research note on Thursday, July 30th. Weiss Ratings reissued a "sell (d-)" rating on shares of Adaptive Biotechnologies in a research note on Friday, July 17th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an "overweight" rating for the company in a research note on Wednesday, May 6th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $24.42.

Insider Activity

In other news, insider Harlan S. Robins sold 492,400 shares of the business's stock in a transaction that occurred on Tuesday, July 21st. The stock was sold at an average price of $21.89, for a total transaction of $10,778,636.00. Following the completion of the sale, the insider owned 812,058 shares in the company, valued at $17,775,949.62. The trade was a 37.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter M. Neupert sold 124,690 shares of the company's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $25.15, for a total value of $3,135,953.50. Following the completion of the transaction, the director directly owned 130,625 shares in the company, valued at $3,285,218.75. The trade was a 48.84% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 2,062,325 shares of company stock valued at $46,659,069. Company insiders own 5.70% of the company's stock.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source